ABBREVIATIONS
CHAPTER 2: OBJECTS AND METHODS
CHAPTER 4: DISCUSSION
CONCLUSION
Through the research results, we have reached some conclusions:
1. Clinical changes, pulmonary ventilation and level of control after 3 months:
- After 3 months of controlled treatment, patients have good clinical progress:
+ The proportion of patients who did not have day and night attacks increased with control treatment time, respectively (27.3%, 80.3% and 78.8% and 42.4%, 83.3 % and 84.8%). Reduction of asthma severity: The rate of first-degree asthma increased significantly after 1, 2 and 3 months of controlled treatment with rates of 33.3%, 80.3% and 84.8%, respectively.
+ The proportion of patients with ACT scores: 25 points increased markedly after 1, 2 and 3 months of controlled treatment with the rates of 27.3%, 80.3%, and 74.2% respectively.
- Changes in pulmonary ventilation and eosinophils count:
+ The percentage of patients increasing FVC, FEV1 ≥ 12% in the well-controlled group was significantly higher than that of the uncontrolled group (67.9% and 88.68% compared to 14.29% and 42.86%) ( p <0.05).
+ 94.3% of patients with normal E leukocyte control had good asthma control after 3 months of treatment (p <0.05).
- Change control level:
+ The number of controlled patients increased after 1, 2, 3 months of treatment, respectively, the rates of 30.3%, 80.3% and 80.3%. Asthma decreased significantly proportionally with the control level (p <0.001).
+ There is a relationship between obese people and uncontrolled asthma level (OR = 0.05 [p = 0.01;% CL = 0.006 - 0.46])
2. Change the concentration of IL-4, IL-5, IL-13, TNF-α serum according to the control level:
- After 3 months of controlled treatment, the average concentration of IL-5 serum in well-controlled patients decreased significantly compared to patients with no control and partial control (p <0.05).
- After 1, 2, and 3 months of controlled treatment, the average concentration of IL-13 and TNF-α serum in the controlled patients was significantly reduced in patients with uncontrolled and partially controlled (p <0, 05).
- There is a relationship between the decrease in IL-5, IL-13, and TNF-α levels compared to before treatment with a controlled level and an association between an increase in IL-5, IL-13, and TNF levels -α compared with pre-treatment with partial and uncontrolled control in patients after 3 months.
From the results of this study, we would like to make the following recommendations:
- Clinical changes, pulmonary air system and control levels in patients under ICS-LABA-controlled treatment follow GINA's guidelines, which are remarkably effective from February and March, so it is necessary to evaluate control results at 2 and 3 months in patients.
- The concentration of IL-5, IL-13 and TNF-α serum changes in parallel with the control level, so in addition to assessing by changing clinical symptoms, pulmonary ventilation parameters can be assessed further. serum IL-5, IL-13, TNFα concentrations in monitoring the response to controlled treatment in asthmatic patients when the treatment is conditional on testin.